Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Affymetrix

This article was originally published in The Gray Sheet

Executive Summary

Acquisition of privately held DNA array technology firm Genetic MicroSystems for 1 mil. shares of common stock valued at about $101 mil. is outlined in a definitive agreement announced Sept. 13. The Woburn, Massachusetts based firm's product line, which includes the GMS 417 arrayer and GMS 418 array scanner, will complement Affymetrix' high-volume GeneChip platform. The deal is expected to close in Jan. 2000. Separately, the U.S. Patent and Trademark Office Board of Patent Appeals and Interferences rules in favor of Affymetrix in patent interference proceedings with Palo Alto, California-based Incyte Pharmaceuticals. The board's decision, which Incyte intends to appeal, says that Incyte did not provide sufficient evidence that Affymetrix' claims were not supported by written description or enablement

You may also be interested in...



Affymetrix

Genetic MicroSystems will operate as a wholly owned facility of Affymetrix following the completion of an acquisition agreement valued at roughly $101 mil. and announced Sept. 13 (1"The Gray Sheet" Sept. 20, p. 20)

Coronavirus Update: Moderna’s Vaccine Shows Signs Of Lasting Protection

The US is to ship only half of doses for Pfizer, Moderna COVID-19 vaccines in the first instance, while Rhizen Pharmaceuticals starts a Phase I trial of a DHODH inhibitor.

UsernamePublicRestriction

Register

OM002409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel